Thromboangiitis obliterans: a review

Authors

  • Martha O. Correa-Posada Department of Angiology, Vascular and Endovascular Surgery. Vía Vascular. Medellín, Colombia
  • John F. García-Velez Department of Angiology, Vascular and Endovascular Surgery. Vía Vascular. Medellín, Colombia
  • Orestes André Hurtado-Mosquera Department of Angiology, Vascular and Endovascular Surgery. Vía Vascular. Medellín, Colombia
  • Miguel A. Sierra-Juárez Department of Angiology, Vascular and Endovascular Surgery, General Hospital of Mexico “Dr. Eduardo Liceaga”, CDMX, Mexico
  • Erick Fernando Hernández Department of General Surgery, General Hospital of Mexico “Dr. Eduardo Liceaga”. CDMX, Mexico
  • Cinthia N. Argüelles Castillo Department of Diagnostic and Therapeutic Imaging, Dr. Manuel Gea Gonzalez Hospital. CDMX, Mexico
  • German E. Mendoza Barrera Department of General Surgery, Kelsey Seybold Clinic, Houston, Texas
  • Alan I. Valderrama-Treviño Department of Angiology, Vascular and Endovascular Surgery, General Hospital of Mexico “Dr. Eduardo Liceaga”, CDMX, Mexico

DOI:

https://doi.org/10.18203/2349-2902.isj20241283

Keywords:

Buerguer's disease, TAO, Vasculitis, Non-atherosclerotic inflammatory vasculitis, Vasculopathies

Abstract

Buerger's disease was initially described by von Winiwarter in 1879 where he described it as thromboangiitis obliterans (TAO), detailing the case of spontaneous gangrene secondary to intimal proliferation. In 1908, Leo Buerger published a complete pathological description based on the amputation of a group of people who later suffered short-term gangrene. Buerger's disease or TAO is defined as a non-atherosclerotic inflammatory vasculitis that affects the small and medium vessels (including arteries and veins) of the lower and upper extremities. Although there are hypotheses about its etiopathogenesis such as the association with exposure to tobacco, few biomedical investigations have been carried out, so its direct causality remains unknown. Diagnosis continues to be a challenge, since the findings tend to be non-specific or inconsistent with suspicion, which is why it is currently based on ruling out other causes such as atherosclerosis and vasculopathies. With current evidence, there are many types of treatments, both pharmacological and non-pharmacological, with the cessation of tobacco consumption having greater evidence of results. It is essential to strengthen basic research as well as clinical trials to standardize management in this type of patient, since it is a disease with a high impact on quality of life.

 

References

Conde ID, Peña C. Buerger’s Disease Tromboangiitis Obliterans. Techn Vascular Interventional Radiol. 2014;17(4):234-40.

Ribieras AJ, Ortiz YY, Liu ZJ, Velazquez OC. Therapeutic angiogenesis in Buerger’s disease: reviewing the treatment landscape. Ther Adv Rare Dis. 2022;30:3:26330040211070295.

Rondón-Carvajal J, Guzmán-Arango C, Cano-Márquez D. Enfermedad de Buerger o el endotelio como laberinto: a propósito de un caso clínico. Med Lab. 2023;27(3):211-21.

Olin JW. Thromboangiitis Obliterans: 110 Years Old and Little Progress Made. J Am Heart Assoc. 2018;7(23):e011214.

Rivera-Chavarría IJ, Brenes-Gutiérrez JD. Thromboangiitis obliterans (Buerger's disease). Ann Med Surg. 2016;7:79-82.

Ochoa CD, Ramírez F, Quintana G, Toro C, Cañas C, Osio LF, et al. Epidemiología de las vasculitis primarias en Colombia y su relación con lo informado para Latinoamérica. Revista Colombiana Reumatol. 2009;16(3):248-63.

Liu Z, Ning W, Liang J, Zhang T, Yang Q, Zhang J, et al. Top 100 cited articles in the thromboangiitis obliterans: a bibliometric analysis and visualized study. Eur J Med Res. 2023;28(1):551.

Pilitsi E, Kennamer B, Trepanowski N, Gonzalez R, Trojanowski M, Phillips T, et al. Cannabis arteritis presenting with Raynaud’s and digital ulcerations: a case‐based review of a controversial thromboangiitis obliterans‐like condition. Clin Rheumatol. 2023;42(7):1981-5.

Banana Y, Bashir H, Boukabous S, Rezziki A, Benzirar A, El Mahi O. Cannabis arteritis: A case report and brief review of the literature. Ann Med Surg. 2022;76:103523.

Shapouri-Moghaddam A, Saeed Modaghegh MH, Reza Rahimi H, Ehteshamfar SM, Tavakol Afshari J. Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review. Iran J Basic Med Sci. 2019;22(3):215-24.

Fazeli B, Ligi D, Keramat S, Maniscalco R, Sharebiani H, Mannello F. Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. Diagnostics. 2021;11(10):1736.

Sharebiani H, Fazeli B, Maniscalco R, Ligi D, Mannello F. The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease). J Clin. Med. 2020;9(4):1036.

Kumar Khanna A, Zeeshan Hakim M. The Management of Ischemic Limb in Thromboangiitis Obliterans (Buerger’s Disease). Indian J Surg. 2021;83:836-44.

Merashli M, Bucci T, Pastori D, Pignatelli P, Arcaro A, Gentile F, et al. A Meta-Analysis of Plasma Homocysteine in Buerger’s Disease. Thromb Haemost. 2022;122(7):1243-6.

Tang X, Guo J, Qi F, Rezaei MJ. Role of non-coding RNAs and exosomal non-coding RNAs in vasculitis: A narrative review. Int J Biol Macromol. 2024;261(2):129658.

Chen B, Deng Y, Wang B, Tian Z, Tong J, Yu B, et al. Integrated analysis of long non-coding RNA-microRNA-mRNA competing endogenous RNAregulatory networks in thromboangiitis Obliterans. Bioengineered. 2021;12(2):12023-37.

Deng Y, Tong J, Shi W, Tian Z, Yu B, Tang J. Thromboangiitis obliterans plasma-derived exosomal miR-223-5p inhibits cell viability and promotes cell apoptosis of human vascular smooth muscle cells by targeting VCAM1. Ann Med. 2021;53(1):1129-41.

Wang C, Zhang Y, Jiang Z, Bai H, Du Z. miR-100 alleviates the inflammatory damage and apoptosis of H2O2-induced human umbilical vein endothelial cells via inactivation of Notch signaling by targeting MMP9. Vascular. 2022;30(1):151-61.

Dai X, Che X. miR-155 for diagnosing thromboangiitis obliterans and its effect on platelet function: a clinical study. Int J Clin Exp Med. 2020;13(2):1277-84.

Małecki R, Zdrojowy R, Adamiec R. Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis. 2009;206(2):328-34.

Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol. 2006;18(1):18-24.

Vijayakumar A, Tiwari R, Kumar Prabhuswamy V. Thromboangiitis Obliterans (Buerger's Disease)-Current Practices. Int J Inflam. 2013;2013:156905.

Szydełko-Paśko U, Przeździecka-Dołyk J, Małecki R, Szuba A, Misiuk-Hojło M. Ocular Manifestations of Buerger’s Disease-A Review of Current Knowledge. Clin Ophthalmol. 2022;16:851-60.

Komai H. Thromboangiitis Obliterans-A Disappearing Disease? Circ J. 2024;88(3):329-30.

Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology. 2007;46(2):192-9.

Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds. 2006;5(2):89-95.

Fakour F, Fazeli B. Visceral bed involvement in thromboangiitis obliterans: a systematic review. Vasc Health Risk Manag. 2019;15:317-53.

Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al. JCS 2017 Guideline on Management of Vasculitis Syndrome-Digest Version. Circ J. 2020;84(2):299-359.

Pu H, Huang Q, Zhang X, Wu Z, Qiu P, Jiang Y, et al. A meta-analysis of randomized controlled trials on therapeutic efficacy and safety of autologous cell therapy for atherosclerosis Obliterans. J Vasc Surg. 2022;75(4):1440-49.

Bradshaw S, Habibollahi P, Soni J, Kolber M, Pillai AK. Popliteal artery entrapment syndrome. Cardiovasc Diagn Ther. 2021;11(5):1159-67.

Bastidas Goyes AR, Mora C, Martín Arsanios D, Orduz K. Systemic lupus erythematosus, a disease conditioned by the environment. Rev Colomb Reumatol. 2021;28(1):12-20.

Chen Q, Chen J, Li J, Cheng Y, Zhang R, Liu Z. Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications. Thromb Res. 2023;230:64-73.

Cacione DG, Macedo CR, Carmo Novaes FD, Baptista-Silva JCC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev. 2020;5(5):CD011033.

Frota Carneiro FC, Almeida BM, Cacione DG. Endovascular treatment for thromboangiitis obliterans (Buerger’s disease). Cochrane Database Syst Rev. 2023;2023(1):CD014886.

Galyfos G, Liakopoulos D, Chamzin A, Sigala F, Filis K. A systematic review and meta-analysis of early and late outcomes after endovascular angioplasty among patients with thromboangiitis obliterans and chronic limb ischemia. J Vasc Surg. 2023;77(5):1534-41.

Le Joncour A, Soudet S, Dupont A, Espitia O, Koskas F, Cluzel P, et al. Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients. J Am Heart Assoc. 2018;7(23):e010677.

Downloads

Published

2024-05-04

Issue

Section

Review Articles